Evofem and Aditxt extend proxy filing deadline to Feb. 14, 2024 via first amendment to merger agreement

Evofem Biosciences, Inc.

First Amendment to Merger Agreement moves Joint Proxy Statement filing date to February 14, 2024.
No other terms of the December 11, 2023 merger agreement were changed.
Merger Sub (Adicure) will merge into Evofem, with Evofem surviving as a wholly-owned subsidiary of Aditxt.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Evofem Biosciences, Inc. amended Agreement and Plan of Merger with Aditxt, Inc., Adicure, Inc. (effective 2024-01-08).

Action: amendment
Agreement: merger
Counterparty: Aditxt, Inc., Adicure, Inc.
Effective: 2024-01-08

Exact text from the filing

On January 8, 2024, the Company, Aditxt and Merger Sub entered into the first amendment to the Merger Agreement (the “First Amendment”), to change the filing date for the Joint Proxy Statement (as defined in the Merger Agreement) to February 14, 2024.

View on SEC.gov

Browse all material agreements →

Evofem Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-002087

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.